S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
The single greatest medical breakthrough of all time? (Ad)
Estonia to buy US rocket artillery system in $200M deal
Rail workers say deal won't resolve quality-of-life concerns
The single greatest medical breakthrough of all time? (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Thousands protest in South Korea in support of truckers
"The Bull Market Is Officially OVER"  (Ad)pixel
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
The single greatest medical breakthrough of all time? (Ad)
Estonia to buy US rocket artillery system in $200M deal
Rail workers say deal won't resolve quality-of-life concerns
The single greatest medical breakthrough of all time? (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Thousands protest in South Korea in support of truckers
"The Bull Market Is Officially OVER"  (Ad)pixel
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
The single greatest medical breakthrough of all time? (Ad)
Estonia to buy US rocket artillery system in $200M deal
Rail workers say deal won't resolve quality-of-life concerns
The single greatest medical breakthrough of all time? (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Thousands protest in South Korea in support of truckers
"The Bull Market Is Officially OVER"  (Ad)pixel
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
The single greatest medical breakthrough of all time? (Ad)
Estonia to buy US rocket artillery system in $200M deal
Rail workers say deal won't resolve quality-of-life concerns
The single greatest medical breakthrough of all time? (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Thousands protest in South Korea in support of truckers
"The Bull Market Is Officially OVER"  (Ad)pixel
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
NASDAQ:GDRX

GoodRx - GDRX Stock Forecast, Price & News

$5.33
+0.17 (+3.29%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.91
$5.33
50-Day Range
$4.06
$5.71
52-Week Range
$3.82
$42.87
Volume
2.83 million shs
Average Volume
2.38 million shs
Market Capitalization
$2.11 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.28

GoodRx MarketRank™ Forecast

Analyst Rating
Hold
2.29 Rating Score
Upside/​Downside
111.5% Upside
$11.28 Price Target
Short Interest
Healthy
3.00% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.41mentions of GoodRx in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-25.00%
From $0.04 to $0.03 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

606th out of 1,034 stocks

Data Processing & Preparation Industry

42nd out of 72 stocks

GDRX stock logo

About GoodRx (NASDAQ:GDRX) Stock

GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was incorporated in 2015 and is headquartered in Santa Monica, California.

Receive GDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GoodRx and its competitors with MarketBeat's FREE daily newsletter.

GDRX Stock News Headlines

GoodRx (NASDAQ:GDRX) Now Covered by Analysts at Citigroup
Why Shares of GoodRx Holdings Fell 18.7% Lower This Week
Why GoodRx Stock Was Plunging Today
GoodRx Reports Third Quarter 2022 Results
Expert Ratings for GoodRx Holdings
See More Headlines
Receive GDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GoodRx and its competitors with MarketBeat's FREE daily newsletter.

GDRX Company Calendar

Last Earnings
11/10/2021
Today
12/03/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Data processing & preparation
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GDRX
Fax
N/A
Employees
756
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.28
High Stock Price Forecast
$45.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+111.5%
Consensus Rating
Hold
Rating Score (0-4)
2.29
Research Coverage
21 Analysts

Profitability

Net Income
$-25,250,000.00
Pretax Margin
-1.59%

Debt

Sales & Book Value

Annual Sales
$745.42 million
Cash Flow
$0.12 per share
Book Value
$1.99 per share

Miscellaneous

Free Float
390,287,000
Market Cap
$2.11 billion
Optionable
Not Optionable
Beta
0.88

Key Executives

  • Mr. Douglas Joseph HirschMr. Douglas Joseph Hirsch (Age 51)
    Co-founder, Co-CEO & Director
    Comp: $927.77k
  • Mr. Trevor  BezdekMr. Trevor Bezdek (Age 44)
    Co-founder, Co-CEO, Sec. & Director
    Comp: $891.68k
  • Mr. Karsten Ian VoermannMr. Karsten Ian Voermann (Age 52)
    CFO & Principal Financial Officer
    Comp: $520.97k
  • Mr. Babak  AzadMr. Babak Azad (Age 49)
    Chief Marketing Officer and SVP of Marketing & Communications
    Comp: $500.4k
  • Mr. Bansi  NagjiMr. Bansi Nagji (Age 57)
    Pres of Healthcare
    Comp: $866.97k
  • Mr. Raj Beri
    Chief Operating Officer
  • Mr. Romin Nabiey (Age 35)
    Chief Accounting Officer & Principal Accounting Officer
  • Ms. Whitney Notaro
    VP of Investor Relations
  • Ms. Vina M. Leite (Age 52)
    Chief People Officer
  • Mr. Justin Fengler
    Sr. VP of Corp. Strategy & Bus. Operations













GDRX Stock - Frequently Asked Questions

Should I buy or sell GoodRx stock right now?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GoodRx in the last year. There are currently 15 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GDRX, but not buy additional shares or sell existing shares.
View GDRX analyst ratings
or view top-rated stocks.

What is GoodRx's stock price forecast for 2023?

21 analysts have issued 1 year price objectives for GoodRx's stock. Their GDRX share price forecasts range from $5.00 to $45.00. On average, they predict the company's share price to reach $11.28 in the next year. This suggests a possible upside of 111.5% from the stock's current price.
View analysts price targets for GDRX
or view top-rated stocks among Wall Street analysts.

How have GDRX shares performed in 2022?

GoodRx's stock was trading at $32.68 on January 1st, 2022. Since then, GDRX stock has decreased by 83.7% and is now trading at $5.33.
View the best growth stocks for 2022 here
.

When is GoodRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our GDRX earnings forecast
.

How were GoodRx's earnings last quarter?

GoodRx Holdings, Inc. (NASDAQ:GDRX) posted its quarterly earnings results on Wednesday, November, 10th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.01 by $0.08. The firm earned $195.10 million during the quarter, compared to the consensus estimate of $196.08 million. GoodRx had a positive trailing twelve-month return on equity of 3.45% and a negative net margin of 8.89%. During the same quarter in the previous year, the company earned ($0.25) EPS.

What guidance has GoodRx issued on next quarter's earnings?

GoodRx updated its fourth quarter 2022 earnings guidance on Tuesday, November, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $175.00 million-$180.00 million, compared to the consensus revenue estimate of $204.24 million.

What other stocks do shareholders of GoodRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GoodRx investors own include Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY), DraftKings (DKNG), GW Pharmaceuticals (GWPH), Rocket Companies (RKT), AT&T (T), Advanced Micro Devices (AMD) and Alteryx (AYX).

When did GoodRx IPO?

(GDRX) raised $900 million in an IPO on Wednesday, September 23rd 2020. The company issued 34,600,000 shares at a price of $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays acted as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers.

What is GoodRx's stock symbol?

GoodRx trades on the NASDAQ under the ticker symbol "GDRX."

Who are GoodRx's major shareholders?

GoodRx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.98%), Light Street Capital Management LLC (1.06%), Marshall Wace LLP (0.91%), Renaissance Technologies LLC (0.56%), Petrus Trust Company LTA (0.55%) and BlackRock Inc. (0.45%). Insiders that own company stock include Abdiel Capital Management, Llc, Agnes Rey-Giraud, Andrew Slutsky, Babak Azad, Bansi Nagji, Douglas Joseph Hirsch, Idea Men, Llc, Karsten Voermann, Lake Group LLC Silver and Trevor Bezdek.
View institutional ownership trends
.

How do I buy shares of GoodRx?

Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GoodRx's stock price today?

One share of GDRX stock can currently be purchased for approximately $5.33.

How much money does GoodRx make?

GoodRx (NASDAQ:GDRX) has a market capitalization of $2.11 billion and generates $745.42 million in revenue each year. The company earns $-25,250,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis.

How many employees does GoodRx have?

The company employs 756 workers across the globe.

How can I contact GoodRx?

GoodRx's mailing address is 233 WILSHIRE BLVD. SUITE 990, SANTA MONICA CA, 90401. The official website for the company is www.goodrx.com. The company can be reached via phone at 855-268-2822 or via email at alex@blueshirtgroup.com.

This page (NASDAQ:GDRX) was last updated on 12/4/2022 by MarketBeat.com Staff